

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No. ANG/2018-19/BSE-13
To

Date: 14.11.2018

Department of Corporate Services,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Ref: BSE Security Code 540694

Sub: Un-Audited Standalone Financial Results for the Half Year ended September 30, 2018

Dear Sir/ Madam,

Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Un-Audited Financial Results of the Company for the Half Year ended September 30, 2018 and the Statement of Assets and Liabilities as at September 30, 2018 as approved by Board of Directors in its meeting held on November 14, 2018 along with the Limited Review Report issued by M/s Ajay K Khanna & Co., Statutory Auditors of the Company.

Kindly take this information on your record.

Thanking You,

Yours Faithfully

For **ANG Lifesciences India Limited**


Rajesh Gupta
(DIN: 01423407)
Managing Director



Factory:

Village: Kishanpura,
Nalagarh Road,
Tehsil: Baddi,
Distt.: Solan,
HP-174101

Regd. Office : SCO-113,
DARBARA COMPLEX,
First Floor, B-BLOCK,
Ranjit Avenue, Amritsar.
Ph. 0183-5133455, 5133458
E mail :- operations@anglifesciences.com
website : www.anglifesciences.com

ANG Lifesciences India Ltd.

CIN : L24230PB2006PLC030341

Registered Office : 113, First Floor, Darbara Complex,
Ranjit Avenue, Amritsar

Email ID : cs@anglifesciences.com, Website : www.anglifesciences.com

UNAUDITED STANDALONE FINANCIAL RESULTS FOR HALF YEAR ENDED
30th SEPTEMBER, 2018

(In Lacs)

Sr. No.	Particulars	Half Year Ended			For the year ended
		30.09.2018	31.03.2018	30.09.2017	31.03.2018
		Unaudited	Audited	Unaudited	Audited
I.	Revenue from operations	5433.67	4684.98	2919.49	7604.47
II.	Other income	8.33	62.82	5.90	68.72
III.	Total Revenue (I + II)	5442.00	4747.81	2925.39	7673.20
IV.	Expenses:				
	(a) Cost of materials consumed	4048.12	3086.53	2234.60	5321.13
	(b) Changes in Inventories	-10.66	250.70	-282.44	-31.74
	(c) Employee benefits expense	315.69	290.74	273.71	564.45
	(d) Finance costs	101.51	82.31	75.75	158.06
	(e) Depreciation and amortization expense	55.49	63.74	55.41	119.15
	(f) Other expenses	594.52	611.08	435.76	1046.84
	Total expenses	5104.67	4385.09	2792.79	7177.88
V.	Profit before exceptional and extraordinary items and tax (III-IV)	337.33	362.71	132.60	495.31
VI.	Exceptional items	0.00	0.00	0.00	0.00
VII.	Profit before extraordinary items and tax (V - VI)	337.33	362.71	132.60	495.31
VIII.	Extraordinary Items	0.00	0.00	0.00	0.00
IX.	Profit before tax (VII- VIII)	337.33	362.71	132.60	495.31
X	Tax expense:				
	(1) Current tax	66.41	75.64	27.85	103.49
	(2) Deferred tax	0.00	19.41	0.00	19.41
	(3) Mat Credit Entitlement	0.00	0.00	0.00	0.00
XI.	Profit (Loss) for the period from continuing operations (VII-VIII)	270.92	267.66	104.75	372.41
XII.	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00
XIII.	Tax expense of discontinuing operations	0.00	0.00	0.00	0.00
XIV.	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	0.00	0.00	0.00	0.00
XV.	Profit (Loss) for the period (XI + XIV)	270.92	267.66	104.75	372.41
XVI.	Earnings per equity share:				
	(a) Basic & Diluted (Rs.)	5.23	5.16	2.25	7.18
	(b) Diluted (Rs.)	5.23	5.16	2.25	7.18



ANG Lifesciences India Ltd.

CIN : L24230PB2006PLC030341

Registered Office : 113, First Floor, Darbara Complex,

Ranjit Avenue, Amritsar

Email ID : cs@anglifesciences.com, Website : www.anglifesciences.com

STANDALONE STATEMENT OF ASSETS AND LIABILITIES

(Amount in Lacs)

Sr. No.	Particulars	Half year ended	Year ended
		30.09.2018	31.03.2018
		Unaudited	Audited
I.	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) <u>Share capital</u>	518.33	518.33
	(b) <u>Reserves and surplus</u>	2069.42	1798.50
	Sub-total-Shareholders' Fund	2587.75	2316.83
2	Non-current liabilities		
	(a) <u>Long-term borrowings</u>	768.40	768.33
	(b) <u>Other Long-term liabilities</u>	42.08	149.82
	(b) <u>Deferred Tax Liabilities (Net)</u>	36.95	36.95
	Sub-total-non Current Liabilities	847.43	955.10
3	Current liabilities		
	(a) <u>Short Term Borrowings</u>	728.09	639.89
	(b) <u>Trade Payables</u>	2609.64	2231.52
	(c) <u>Other current liabilities</u>	434.84	568.86
	(d) <u>Short-term provisions</u>	172.43	104.31
	Sub-total-Current Liabilities	3945.00	3544.60
	TOTAL EQUITY AND LIABILITIES	7380.18	6816.53
II.	ASSETS		
	Non-current assets		
1	(a) <u>Fixed assets</u>		
	(i) <u>Tangible assets</u>	2056.82	2104.13
	(b) <u>Deferred Tax Assets (Net)</u>	0.00	0.00
	(c) <u>Other non-current assets</u>	22.93	22.93
	(d) <u>Other non-current Investments</u>	2.00	2.00
	Sub-total-non Current Assets	2081.75	2129.06
2	Current assets		
	(a) <u>Inventories</u>	634.71	774.29
	(b) <u>Trade receivables</u>	3977.76	3215.02
	(c) <u>Cash and cash equivalents</u>	166.31	147.94
	(d) <u>Short-term loans and advances</u>	519.65	550.21
	Sub-total-Current Assets	5298.43	4687.46
	TOTAL ASSETS	7380.18	6816.53



Notes :

- 1) The Audit Committee has reviewed these results and the Board of Directors have approved the above results at their meeting held on November 14, 2018.
- 2) As the Company's business activities falls with in a single segment, the disclosure requirement of the Accounting Standard AS(17) "Segment Reporting" as notified under Section 133 of the Companies Act, 2013 read with Rule7 of the Companies (Accounts) Rules 2014 are not applicable.
- 3) The figures for the corresponding previous period have been regrouped/ reclassified wherever considered necessary to confirm the figures in the current period.
- 4)As per MCA Notification dated 16.02.2015, companies whose shares are listed on SME exchange as referred in Chapter XB of SEBI (Issue of Capital Disclosure requirements) Regulations 2009 are exempted from the compulsory requirements of adoption of IND-AS. As the company is covered under the exempted category, the company has not adopted IND -AS for preparation of Financials Results.
- 5) There were no Investors complaints pending as on 30.09.2018.

For ANG Lifesciences India Limited


(Managing Director)
Rajesh Gupta
(DIN : 01423407)



Date : 14.11.2018

Place : Amritsar



INDEPENDENT AUDITORS LIMITED REVIEW REPORT ON THE UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2018

To,

The Board of Directors,
ANG Lifesciences India Limited
SCO 113, Darbara Complex,
First Floor, B-Block,
Ranjit Avenue, Amritsar-143001

We have reviewed the accompanying statement of unaudited financial results of **ANG Lifesciences India Limited** for the period ended on 30th September, 2018. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Ajay K Khanna & Co.
Chartered Accountants**



**(Bhupinder Singh)
Partner**

M. No: 513899

FRN : 012303N

Date : 14-11-2018

Place: Amritsar